US Bancorp DE Has $148.02 Million Stock Holdings in Merck & Co., Inc. (NYSE:MRK)


Share on StockTwits

US Bancorp DE lessened its stake in Merck & Co., Inc. (NYSE:MRK) by 2.1% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,920,085 shares of the company’s stock after selling 40,336 shares during the quarter. US Bancorp DE’s holdings in Merck & Co., Inc. were worth $148,020,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Norges Bank bought a new stake in Merck & Co., Inc. in the fourth quarter worth approximately $2,250,767,000. Nuveen Asset Management LLC grew its position in Merck & Co., Inc. by 20.4% in the fourth quarter. Nuveen Asset Management LLC now owns 24,251,965 shares of the company’s stock worth $1,983,811,000 after acquiring an additional 4,112,158 shares in the last quarter. Morgan Stanley grew its position in Merck & Co., Inc. by 16.7% in the fourth quarter. Morgan Stanley now owns 22,569,366 shares of the company’s stock worth $1,846,174,000 after acquiring an additional 3,221,509 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Merck & Co., Inc. by 0.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 18,956,192 shares of the company’s stock worth $1,550,617,000 after acquiring an additional 139,485 shares in the last quarter. Finally, California Public Employees Retirement System grew its position in Merck & Co., Inc. by 31.6% in the fourth quarter. California Public Employees Retirement System now owns 13,542,412 shares of the company’s stock worth $1,107,769,000 after acquiring an additional 3,252,367 shares in the last quarter. Hedge funds and other institutional investors own 72.86% of the company’s stock.

Several analysts recently issued reports on the stock. SVB Leerink decreased their price objective on shares of Merck & Co., Inc. from $103.00 to $102.00 and set an “outperform” rating for the company in a report on Friday. Cantor Fitzgerald restated an “overweight” rating on shares of Merck & Co., Inc. in a research note on Friday, February 5th. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $97.22.

Shares of NYSE MRK traded up $0.10 during mid-day trading on Tuesday, hitting $76.08. The company’s stock had a trading volume of 239,161 shares, compared to its average volume of 11,885,203. The stock has a market cap of $192.51 billion, a price-to-earnings ratio of 16.81, a price-to-earnings-growth ratio of 1.89 and a beta of 0.43. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.30 and a quick ratio of 1.00. Merck & Co., Inc. has a one year low of $71.71 and a one year high of $87.80. The company’s fifty day simple moving average is $76.83 and its 200-day simple moving average is $78.38.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Thursday, April 29th. The company reported $1.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.63 by ($0.23). Merck & Co., Inc. had a net margin of 24.33% and a return on equity of 53.83%. The business had revenue of $12.08 billion during the quarter, compared to the consensus estimate of $12.71 billion. During the same period last year, the business posted $1.50 EPS. The firm’s revenue for the quarter was up .2% compared to the same quarter last year. On average, sell-side analysts predict that Merck & Co., Inc. will post 5.9 EPS for the current year.

Merck & Co., Inc. Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products.

Recommended Story: How mutual funds make money

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.